Dr. Tuteja is a clinical pharmacist and translational researcher with expertise in genomic, translational and implementation research. Her work focuses on 1) implementation of pharmacogenomics into clinical care to improve patient outcomes using an implementation science approach; 2) discovery of novel pharmacogenomic markers of drug response using electronic health record data (EHR) coupled with large DNA repositories; and 3) mechanistic studies in human subjects involving evoked pharmacological perturbations coupled with multi-omic data. Dr. Tuteja received her Doctor of Pharmacy degree from the University of Michigan and her Masters in Translational Research at the University of Iowa. She completed a post-doctoral fellowship in pharmacogenomics at the University of Pennsylvania. She established the first pharmacist-run pharmacogenetics clinic within Penn Medicine where she consults with patients requesting pharmacogenetic testing.
Using Implementation Science to Enhance Adoption of Pharmacogenetics
Pharmacogenetic (PGx) testing has the potential to prevent drug-related adverse events and improve patient outcomes, but the process of integrating genomic data into clinical practice has been challenging. Methods and strategies established by the discipline of implementation science can be leveraged to accelerate adoption of PGx.
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.